Log in to search using one of your social media accounts:

 

Seattle Genetics drug gets OK for additional cancer therapies in Europe

Seattle Genetics’s treatment for high-risk Hodgkin lymphoma patients can now be marketed in Europe. Seattle Genetics (Nasdaq: SGEN) says its global distribution partner Takeda Pharmaceutical Co. has received permission from the European Commission to market Adcetris in 28 EU member countries and Norway, Liechtenstein and Iceland. Adcetris is already commercially available in more than 60 countries around the world, including throughout the EU for two other uses — relapsed Hodgkin lymphoma and…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

In this study, we found discrepancies in iNKT cell responses against two T cell-origin cell lines (Jurkat and Molt-4). Human iNKT cells exhibited more intensive cytotoxicity and less efficient cytokine production in response to Fas-bearing Jurkat cells than those to the Fas-negative tumor cells (Molt-4 and myeloid-derived K562). The imbalanced cytokine/cytotoxicity responses of iNKT cells against Jurkat cells were CD1d-dependent and relied mostly on Fas/FasL interaction. The impairment in cytokine production could be overcome by Fas/FasL blocking antibodies and exogenous IL-2. Elevated CD1d levels as well as CD1d and Fas c...
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
Authors: Buoninfante OA, Pilzecker B, Aslam MA, Zavrakidis I, van der Wiel R, van de Ven M, van den Berk PCM, Jacobs H Abstract DNA damage tolerance (DDT) enables replication to continue in the presence of a damaged template and constitutes a key step in DNA interstrand crosslink repair. In this way DDT minimizes replication stress inflicted by a wide range of endogenous and exogenous agents, and provides a critical first line defense against alkylating and platinating chemotherapeutics. Effective DDT strongly depends on damage-induced, site-specific PCNA-ubiquitination at Lysine (K) 164 by the E2/E3 complex (RAD6/...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
This article is intended to provide readers with an overview of chemistry, pharmacokinetic, pharmacodynamic and safety profile of brigatinib, which addresses an unmet medical need.
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
The Food and Drug Administration on Tuesday approved a second indication for a revolutionary cancer therapy initially developed by researchers at the University of Pennsylvania's Abramson Cancer Center. The FDA cleared Kymriah, a personalized cellular therapy marketed by Novartis, for use in patients with advanced non-Hodgkin's lymphoma. The FDA specifically approved Kymriah for the treatment of certain adult patients with relapsed or refractory diffuse large B-cell lymphoma. The American Cancer …
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Cancer therapies commonly slow disease and most patients ultimately relapse. Here we show at the single-cell level that cutaneous lymphoma cells are programmed to occupy a rare transient, drug-resistant state. Our work defines a panel of drug-resistance markers allowing identification of this cellular subset in patients. Single-cell analyses reveal a small fraction of cells resisting commonly used drugs such as doxorubicin, vorinostat, and methotrexate. In cell fate analyses, we observed that drug treatment leads to selective survival of label-retaining cells leading to re-growth of xenograft tumors consistent with a relap...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Carcinogenesis and Cancer Genetics Source Type: research
This article is intended to provide readers with an overview of chemistry, pharmacokinetic, pharmacodynamic and safety profile of brigatinib, which addresses an unmet medical need.
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Cancer therapies commonly slow disease and most patients ultimately relapse. Here we show at the single-cell level that cutaneous lymphoma cells are programmed to occupy a rare transient, drug-resistant state. Our work defines a panel of drug-resistance markers allowing identification of this cellular subset in patients. Single-cell analyses reveal a small fraction of cells resisting commonly used drugs such as doxorubicin, vorinostat, and methotrexate. In cell fate analyses, we observed that drug treatment leads to selective survival of label-retaining cells leading to re-growth of xenograft tumors consistent with a relap...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Carcinogenesis and Cancer Genetics Source Type: research
Authors: Chekkat N, Lombardo CM, Seguin C, Lechner MC, Dufour F, Nominé Y, De Giorgi M, Frisch B, Micheau O, Guichard G, Altschuh D, Fournel S Abstract Tumor Necrosis Factor Receptor Apoptosis Inducing Ligand (TRAIL) appears as an interesting candidate for targeted cancer therapy as it induces apoptosis in cancer cells without toxicity to normal cells. TRAIL elicits apoptosis through agonist death receptor TRAIL-R1 and TRAIL-R2 engagement. Nevertheless, recombinant soluble TRAIL and monoclonal antibodies against these receptors demonstrated insufficient efficacy in clinical trials. This may be explained by t...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: Available online 26 March 2018 Source:Journal of Trace Elements in Medicine and Biology Author(s): Marzena Matejczyk, Grzegorz Świderski, Renata Świsłocka, Stanisław Józef Rosochacki, Włodzimierz Lewandowski The most important problems of anti-cancer therapy include the toxicity of the drugs applied to healthy cells and the multi-drug cells resistance to chemotherapeutics. One of the most commonly used anticancer drugs is doxorubicin (DOX) used to treat certain leukemias and non-Hodgkin’s lymphomas, as well as bladder, breast, stomach, lung, ovarian, thyroid, multiple myeloma and other ...
Source: Journal of Trace Elements in Medicine and Biology - Category: Biochemistry Source Type: research
, De Simone M, Marrelli D, Saragoni L, Rausei S, Pallabazzer G, Roviello F, Cassoni P, Sapino A, Bass A, Giordano S Abstract Patient-Derived Xenografts (PDXs), entailing implantation of cancer specimens in immunocompromised mice, are emerging as a valuable translational model that could help validate biologically relevant targets and assist the clinical development of novel therapeutic strategies for gastric cancer. More than 30% of PDXs generated from gastric carcinoma samples developed human B-cell lymphomas instead of gastric cancer. These lymphomas were monoclonal, Epstein Barr Virus (EBV) positive, originated...
Source: Neoplasia - Category: Cancer & Oncology Authors: Tags: Neoplasia Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Health | Health Management | Liechtenstein Health | Lymphoma | Pharmaceuticals